Franzén, Frans Mikael

Franz Michael Franzén f. 9.2.1772 i Uleåborg d. 14.8.1847 i Säbrå, Härnösand, Sverige Frans Michael Franzén är den första utpräglade förromantikern i den finländska litteraturen och har gått till historien även som begåvad akademiker, biskop och tidningsman.

Pakkala, Teuvo

Teuvo Pakkala, urspr. Theodor Oskar Frosterus f. 9.4.1862 i Uleåborg d. 7.5.1925 i Kuopio Teuvo Pakkala var en av 1800-talets mest centrala realistiska författare, och särskilt känd för sina barnskildringar i novellform. I sina verk Vaaralla (sv. I Vaara) från 1891 och Elsa från 1894 tar Pakkala också i bruk naturalismens stilmedel och ideal i skildringen av destruktiva kvinnoöden. I hans produktion betonas speciellt en ny, modern människobild, baserad på djuppsykologi. Också i barnskildringarna kombineras en psykologiskt inkännande skildring med objektivt betraktande. Barngestalterna är trovärdigt beskrivna komplexa karaktärer, även om den samtida kritiken ofta inte insåg värdet i dessa noveller. Pakkala gav också ut tre dramer. Sånglustspelet Tukkijoella (sv. Timmerflottare) från 1896, som utnyttjar timmerflottarromantiska stämningar, är en av tidernas mest populära finska dramer i hemlandet. http://www.kansallisbiografia.fi/kb/artikkeli/2841/

Siljo, Juhani

Juhani Siljo, urspr. Johan Alarik Siljo, fram till år 1906 Sjögren f. 3.5.1888 i Uleåborg d. 6.5.1918 i Tammerfors Sekelskiftesdiktaren Juhani Siljo är speciellt känd för sin etiska strävan och sitt letande efter självet i filosoferna Kierkegaards och Nietzsches anda. Denna, i finsk litteratur kända ”Siljolinje” (”Siljon linja”), fick en fortsättning framför allt i poesi av Uuno Kailas, Aaro Hellaakoski och Helvi Juvonen, samt i 1920-talets fackelbärares (Tulenkantajat-generationens) litterära produktion. Dominerande teman i Siljos postumt utgivna samling Selvään veteen (sv. Mot öppet vatten) från 1919 är byggandet av självet, kompromisslöshet och vilja, centrala tematiska spår även i diktarens övriga produktion. Också kärleksdikter ingår i produktionen. I dem kombineras sinnlighet med askes och livsrädsla. Siljos poesi fick särskilt stor uppskattning på 1940-talet. Han var också en av pionjärerna inom den finska, aforistiska diktningen. http://www.kansallisbiografia.fi/kb/artikkeli/2848/

Uleåborg

Helsingfors : A.W. Gröndahl & A.C. Öhman 1845 : Dresden, Adler u. Dietze

Poetyckie dialogi Czesława Miłosza i Tadeusza Różewicza

Wydział Filologii Polskiej i Klasycznej

An Isoflavone From Dipteryx Alata Vogel Is Active Against The In Vitro Neuromuscular Paralysis Of Bothrops Jararacussu Snake Venom And Bothropstoxin I, And Prevents Venom-induced Myonecrosis.

Snakebite is a neglected disease and serious health problem in Brazil, with most bites being caused by snakes of the genus Bothrops. Although serum therapy is the primary treatment for systemic envenomation, it is generally ineffective in neutralizing the local effects of these venoms. In this work, we examined the ability of 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM), an isoflavone from Dipteryx alata, to neutralize the neurotoxicity (in mouse phrenic nerve-diaphragm preparations) and myotoxicity (assessed by light microscopy) of Bothrops jararacussu snake venom in vitro. The toxicity of TM was assessed using the Salmonella microsome assay (Ames test). Incubation with TM alone (200 μg/mL) did not alter the muscle twitch tension whereas incubation with venom (40 μg/mL) caused irreversible paralysis. Preincubation of TM (200 μg/mL) with venom attenuated the venom-induced neuromuscular blockade by 84% ± 5% (mean ± SEM; n = 4). The neuromuscular blockade caused by bothropstoxin-I (BthTX-I), the major myotoxic PLA2 of this venom, was also attenuated by TM. Histological analysis of diaphragm muscle incubated with TM showed that most fibers were preserved (only 9.2% ± 1.7% were damaged; n = 4) compared to venom alone (50.3% ± 5.4% of fibers damaged; n = 3), and preincubation of TM with venom significantly attenuated the venom-induced damage (only 17% ± 3.4% of fibers damaged; n = 3; p < 0.05 compared to venom alone). TM showed no mutagenicity in the Ames test using Salmonella strains TA98 and TA97a with (+S9) and without (-S9) metabolic activation. These findings indicate that TM is a potentially useful compound for antagonizing the neuromuscular effects (neurotoxicity and myotoxicity) of B. jararacussu venom.

Nebivolol Reduces Central Blood Pressure In Stage I Hypertensive Patients: Experimental Single Cohort Study.

Assessment of central blood pressure (BP) has grown substantially over recent years because evidence has shown that central BP is more relevant to cardiovascular outcomes than peripheral BP. Thus, different classes of antihypertensive drugs have different effects on central BP despite similar reductions in brachial BP. The aim of this study was to investigate the effect of nebivolol, a β-blocker with vasodilator properties, on the biochemical and hemodynamic parameters of hypertensive patients. Experimental single cohort study conducted in the outpatient clinic of a university hospital. Twenty-six patients were recruited. All of them underwent biochemical and hemodynamic evaluation (BP, heart rate (HR), central BP and augmentation index) before and after 3 months of using nebivolol. 88.5% of the patients were male; their mean age was 49.7 ± 9.3 years and most of them were overweight (29.6 ± 3.1 kg/m2) with large abdominal waist (102.1 ± 7.2 cm). There were significant decreases in peripheral systolic BP (P = 0.0020), diastolic BP (P = 0.0049), HR (P < 0.0001) and central BP (129.9 ± 12.3 versus 122.3 ± 10.3 mmHg; P = 0.0083) after treatment, in comparison with the baseline values. There was no statistical difference in the augmentation index or in the biochemical parameters, from before to after the treatment. Nebivolol use seems to be associated with significant reduction of central BP in stage I hypertensive patients, in addition to reductions in brachial systolic and diastolic BP.

Predictive Value Of Phase I Trials For Safety In Later Trials And Final Approved Dose: Analysis Of 61 Approved Cancer Drugs.

Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safety of new agents. We compared data from phase I and registration trials to determine whether early trials predicted later safety and final dose. We searched the U.S. Food and Drug Administration (FDA) website for drugs approved in nonpediatric cancers (January 1990-October 2012). The recommended phase II dose (R2PD) and toxicities from phase I were compared with doses and safety in later trials. In 62 of 85 (73%) matched trials, the dose from the later trial was within 20% of the RP2D. In a multivariable analysis, phase I trials of targeted agents were less predictive of the final approved dose (OR, 0.2 for adopting ± 20% of the RP2D for targeted vs. other classes; P = 0.025). Of the 530 clinically relevant toxicities in later trials, 70% (n = 374) were described in phase I. A significant relationship (P = 0.0032) between increasing the number of patients in phase I (up to 60) and the ability to describe future clinically relevant toxicities was observed. Among 28,505 patients in later trials, the death rate that was related to drug was 1.41%. In conclusion, dosing based on phase I trials was associated with a low toxicity-related death rate in later trials. The ability to predict relevant toxicities correlates with the number of patients on the initial phase I trial. The final dose approved was within 20% of the RP2D in 73% of assessed trials.

Pyrimidine-5'-nucleotidase Campinas, A New Mutation (p.r56g) In The Nt5c3 Gene Associated With Pyrimidine-5'-nucleotidase Type I Deficiency And Influence Of Gilbert's Syndrome On Clinical Expression.

Pyrimidine-5'-nucleotidase type I (P5'NI) deficiency is an autosomal recessive condition that causes nonspherocytic hemolytic anemia, characterized by marked basophilic stippling and pyrimidine nucleotide accumulation in erythrocytes. We herein present two African descendant patients, father and daughter, with P5'N deficiency, both born from first cousins. Investigation of the promoter polymorphism of the uridine diphospho glucuronosyl transferase 1A (UGT1A) gene revealed that the father was homozygous for the allele (TA7) and the daughter heterozygous (TA6/TA7). P5'NI gene (NT5C3) gene sequencing revealed a further change in homozygosity at amino acid position 56 (p.R56G), located in a highly conserved region. Both patients developed gallstones; however the father, who had undergone surgery for the removal of stones, had extremely severe intrahepatic cholestasis and, liver biopsy revealed fibrosis and siderosis grade III, leading us to believe that the homozygosity of the UGT1A polymorphism was responsible for the more severe clinical features in the father. Moreover, our results show how the clinical expression of hemolytic anemia is influenced by epistatic factors and we describe a new mutation in the P5'N gene associated with enzyme deficiency, iron overload, and severe gallstone formation. To our knowledge, this is the first description of P5'N deficiency in South Americans.